• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨保护素与慢性肾脏病患者冠状动脉和主动脉钙化的进展

Osteoprotegerin and progression of coronary and aortic calcifications in chronic kidney disease.

作者信息

Mesquita M, Demulder A, Wolff F, Mélot C, Damry N, Dratwa M, Bergmann P

机构信息

Clinic of Nephrology, CHU Brugmann, Brussels, Belgium.

出版信息

Transplant Proc. 2010 Nov;42(9):3444-9. doi: 10.1016/j.transproceed.2010.09.129.

DOI:10.1016/j.transproceed.2010.09.129
PMID:21094794
Abstract

Vascular calcifications (VCs) are important predictors of cardiovascular mortality in patients with chronic kidney disease (CKD). We have shown previously that osteoprotegerin (OPG), a potential early biomarker for VC, was an independent predictor of mortality in CKD patients. The aim of our study was to follow longitudinally coronary and aortic VCs. VCs were measured using Siemens 16 detector CT in a group of predialysis and hemodialyzed patients before and after a follow-up of 4 years. Some of these patients were transplanted in the meantime. Renal function, calcium, phosphate, iPTH, hs-CRP (high sensitive protein C reactive), and OPG serum levels were also compared. VCs progressed in predialysis, hemodialyzed, and transplanted patients but the progression was not the same in all arterial beds. A progression of coronary calcifications was observed in predialysis and transplanted patients, while aortic calcifications worsened significantly only in hemodialyzed patients. OPG serum levels and hs-CRP were significantly lower among transplanted patients. We concluded that VC depends on the severity of the kidney disease. Transplanted patients are not protected from VC, yet their OPG serum levels were significantly lower, suggesting that there is no link between between OPG levels and severity of VC. Longer follow-up of these patients would be necessary to assess whether a decline in OPG correlates with better survival.

摘要

血管钙化(VCs)是慢性肾脏病(CKD)患者心血管死亡的重要预测指标。我们之前已经表明,骨保护素(OPG)作为VC的一种潜在早期生物标志物,是CKD患者死亡率的独立预测指标。我们研究的目的是对冠状动脉和主动脉VCs进行纵向随访。在一组未透析和已透析患者中,使用西门子16层螺旋CT在随访4年前后测量VCs。在此期间,其中一些患者接受了移植。同时还比较了肾功能、钙、磷、iPTH、hs-CRP(高敏C反应蛋白)和OPG血清水平。未透析、已透析和移植患者的VCs均有进展,但在所有动脉床中的进展情况并不相同。在未透析和移植患者中观察到冠状动脉钙化有进展,而仅在已透析患者中主动脉钙化显著恶化。移植患者的OPG血清水平和hs-CRP显著较低。我们得出结论,VC取决于肾脏疾病的严重程度。移植患者并不能免受VC影响,但其OPG血清水平显著较低,这表明OPG水平与VC严重程度之间没有关联。对这些患者进行更长时间的随访,以评估OPG的下降是否与更好的生存率相关是必要的。

相似文献

1
Osteoprotegerin and progression of coronary and aortic calcifications in chronic kidney disease.骨保护素与慢性肾脏病患者冠状动脉和主动脉钙化的进展
Transplant Proc. 2010 Nov;42(9):3444-9. doi: 10.1016/j.transproceed.2010.09.129.
2
A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients.血浆骨保护素水平的截断值可能预测慢性肾脏病患者冠状动脉钙化的存在。
Nephrol Dial Transplant. 2009 Nov;24(11):3389-97. doi: 10.1093/ndt/gfp301. Epub 2009 Jul 2.
3
Serum levels of calcification inhibition proteins and coronary artery calcium score: comparison between transplantation and dialysis.血清钙化抑制蛋白水平与冠状动脉钙化积分:移植与透析的比较
Am J Nephrol. 2007;27(1):75-83. doi: 10.1159/000099095. Epub 2007 Jan 26.
4
Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification.除血管钙化外,骨保护素升高与4期和5期慢性肾脏病患者的全因死亡率相关。
Nephrol Dial Transplant. 2009 Oct;24(10):3157-62. doi: 10.1093/ndt/gfp253. Epub 2009 Jun 2.
5
Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification.严重动脉钙化的血液透析患者血浆中骨保护素水平升高。
Ther Apher Dial. 2018 Oct;22(5):519-529. doi: 10.1111/1744-9987.12681. Epub 2018 Jul 4.
6
Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease.血浆骨保护素是慢性肾脏病患者死亡的独立危险因素及冠状动脉钙化的早期生物标志物。
Clin Chem Lab Med. 2009;47(3):339-46. doi: 10.1515/CCLM.2009.075.
7
Calcium and osteoprotegerin levels predict the progression of the abdominal aortic calcifications after kidney transplantation.钙和护骨素水平可预测肾移植后腹主动脉钙化的进展。
Transplantation. 2013 Jul 15;96(1):42-8. doi: 10.1097/TP.0b013e3182934cee.
8
Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.碳酸镧对比含钙的磷结合剂对血液透析患者主动脉钙化的抑制作用:一项初步的随机对照试验。
Nephrology (Carlton). 2011 Mar;16(3):290-8. doi: 10.1111/j.1440-1797.2010.01412.x.
9
Can osteoprotegerin be used to identify the presence and severity of coronary artery disease in different clinical settings?骨保护素能否用于在不同临床环境中识别冠心病的存在和严重程度?
Atherosclerosis. 2014 Oct;236(2):230-6. doi: 10.1016/j.atherosclerosis.2014.07.013. Epub 2014 Jul 21.
10
Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients.骨生物标志物有助于分级非透析慢性肾脏病患者冠状动脉钙化的严重程度。
PLoS One. 2012;7(5):e36175. doi: 10.1371/journal.pone.0036175. Epub 2012 May 2.

引用本文的文献

1
Serum OPG and RANKL Levels as Risk Factors for the Development of Cardiovascular Calcifications in End-Stage Renal Disease Patients in Hemodialysis.血清骨保护素和核因子κB受体活化因子配体水平作为血液透析终末期肾病患者心血管钙化发生的危险因素
Life (Basel). 2023 Feb 6;13(2):454. doi: 10.3390/life13020454.
2
Osteoprotegerin is a marker of cardiovascular mortality in patients with chronic kidney disease stages 3-5.骨保护素是慢性肾脏病 3-5 期患者心血管死亡率的标志物。
Sci Rep. 2021 Jan 28;11(1):2473. doi: 10.1038/s41598-021-82072-z.
3
Relationship between serum osteoprotegerin and vascular calcifications in hemodialysis patients.
血液透析患者血清骨保护素与血管钙化之间的关系。
Egypt Heart J. 2017 Jun;69(2):149-155. doi: 10.1016/j.ehj.2017.02.004. Epub 2017 Mar 9.
4
Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease.蛋白质组学生物标志物组合:慢性肾脏病的新见解
Dis Markers. 2016;2016:3185232. doi: 10.1155/2016/3185232. Epub 2016 Sep 7.
5
Receptor activator of nuclear factor κB ligand/osteoprotegerin axis and vascular calcifications in patients with chronic kidney disease.核因子κB受体活化因子配体/骨保护素轴与慢性肾脏病患者的血管钙化
World J Nephrol. 2016 Jan 6;5(1):1-5. doi: 10.5527/wjn.v5.i1.1.
6
Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease.在3至5期慢性肾脏病患者中,血浆骨保护素水平升高与全因死亡风险及动脉粥样硬化相关。
Braz J Med Biol Res. 2014 Nov;47(11):995-1002. doi: 10.1590/1414-431x20144007. Epub 2014 Aug 22.